Influence of Liraglutide on Diastolic Cardiac Function and Myocardial Perfusion as Determined by Magnetic Resonance Imaging in Patients With Type 2 Diabetes: a Double-blind Randomized Parallel-group Trial
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Change in diastolic properties as assessed by CMR.
研究概览
简要总结
The purpose of this study is to determine whether liraglutide a GLP-1 analogue are effective in the treatment of diastolic dysfunction in type 2 diabetes patients analyzed by cardiac MRI. Secondary if the treatment has any effect on the perfusion of the heart on a cardiac-MRI.
详细描述
Aim: To test if treatment with liraglutide a GLP-1 analogue in 18 weeks improves diastolic performance in type 2 diabetes (DM2) patients with diastolic dysfunction, compared to placebo. Furthermore, analyzing cardiac MRI indices of fibrosis and the effect on myocardial perfusion.
The investigators find that especially diastolic dysfunction is of interest, because it is highly overrepresented in DM2 patients and no treatment exists. Glucagon-like peptide 1 analogue could be a possible treatment agent, by increasing the energy level in the myocardium. No previous study has tested the effect of treatment with a glucagon-like peptide 1 analogue on diastolic dysfunction.
Design: A randomised double-blinded placebo-controlled clinical trial. Sample size: 40 patients, 20 in each group. The superior inter-study reproducibility results in considerably lower calculated sample sizes (reductions of 55% to 93%) required by cardiac MR compared with echocardiography to show clinically relevant changes. Power calculations show that only 30 patients are needed form our primary outcome, to allow for dropouts the investigators have chosen to include 40 patients.
Intervention: After randomization, patients will be treated with placebo or liraglutide (up to 1.8 mg s.c. once daily). Total treatment period will be 18 weeks. A cardiac MRI scan and an echocardiography will be preformed at baseline and after 18 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patient fully capable of informed consent
- •Informed consent
- •Age 18-80 years (both years inclusive)
- •T2DM diagnosed at least 3 months prior to visit 0
- •NYHA class I-III at visit 0
- •E/e* ≥ 9 or e* (lateral) ≤10 cm/sec, or both
- •LVEF > 50%
- •LVEDV/BSA < 97 ml/m2
- •Stable on heart medication for 6 weeks prior to randomisation
- •Stable on antidiabetic treatment for 30 days prior to randomisation
- •T2DM must be either treated with one or more oral anti-diabetic drugs or treated with human NPH-insulin or long-acting insulin analogue, alone or in combination with oral drugs
排除标准
- •Lack of consent.
- •NYHA class IV
- •Type 1 diabetes mellitus
- •Incretin-based therapy (GLP-1 receptor agonists; exenatide, liraglutide or other and DPP-IV inhibitors) within 30 days prior to randomisation (visit 1)
- •Glitazon therapy within 30 days prior to randomisation (visit 1)
- •Hypertension with inadequate blood pressure control: Systolic blood pressure > 140 mmHg and/or diastolic blood pressure >85 mmHg*
- •Supine systolic blood pressure <85 mmHg measured at visit 0
- •Significant valvular heart disease
- •Hypertrophic cardiomyopathy, ARVC/D, non-compaction or amyloidosis
- •Myocardial infarction, unstable angina, angina on exertion (≥CCS class 2) or coronary revascularization within 3 months prior to randomisation (visit 1)
- •Hospitalisation due to incompensated heart disease within 30 days to randomisation (visit 1)
- •HbA1c >10% at visit 0
- •eGFR< 60 ml/min/1,73 m2 at visit 0
- •Liver disease with aspartate aminotransferase/alanine aminotransferase >3 times upper limit of normal measured at visit 0**
- •Hypokalaemia (P-potassium <3.5 mmol/L) or hyperkalaemia (P-potassium >5.5 mmol/L) measured at visit 0**
- •Anaemia (haemoglobin <6.5 mmol/L) measured at visit 0**
- •Conditions that may be associated with changes in markers of fibroses or collagen turnover (eg. on-going or active rheumatological disease requiring anti-inflammatory agents, immunosuppression, pulmonary fibrosis, active cancer)
- •Prolonged use (> 2 weeks) of glucocorticoids or NSAIDs within 2 weeks prior to visit 0
- •Women of childbearing potential who are not on acceptable contraception. See below.
- •Pregnant or breastfeeding women
- •Cancer (except basal cell skin cancer or squamous cell skin cancer) unless complete remission for ≥ 5 years
- •Alcohol/drug abuse
- •Chronic or previous acute pancreatitis
- •History of thyroid adenoma or carcinoma
- •Inflammatory bowel disease
- •Clinical signs of diabetic gastroparesis
- •ICD/pacemaker or other contraindications to MRI scan
- •Severe claustrophobia
- •Atrial fibrillation
- •Contraindications to glycopyrrolate: closed-angle glaucoma, prostate hyperplasia, tachycardia, bladder atony, cardia insufficiency, non-congenital pylorus stenosis and gastroparesis
- •Known or suspected hypersensitivity to trial product or related products
- •Current participation in any other clinical intervention trial
- •Receipt of an investigational drug with 30 days prior to visit 0
- •Other concominant disease or treatment that according to investigator's assessment makes the patient unsuitable for participation in the study
- •Measured twice at visit
- •In case of elevation, an ambulatory (24-hour) blood pressure will be performed, and the result of this will be conclusive
- •Measured at visit 0 with the possibility of one repeat analysis within a week, and the last measured value will be conclusive.
研究组 & 干预措施
Liraglutide arm
Patients will be treated with liraglutide (up to 1.8 mg s.c. once daily). Total treatment period will be 18 weeks.
干预措施: Liraglutide (Drug)
Placebo arm
Patients will be treated with placebo (up to equal to 1.8 mg drug dose s.c. once daily). Total treatment period will be 18 weeks. The study will be placebo-controlled with placebo as an add-on to conventional diabetes treatment. Thus, no patient will receive a sub-standard treatment.
干预措施: Placebo (Drug)
结局指标
主要结局
Change in diastolic properties as assessed by CMR.
时间窗: Measured in week 18 and compared to baseline.
LV peak filling rate (ml/s) (before and after glycopyrolate)
次要结局
- MRI indices of myocardial perfusion(Measured in week 18 and compared to baseline.)
- Echocardiographic indices of diastolic dysfunction(Measured in week 18 and compared to baseline.)
研究者
Annemie Stege Bojer
MD
Rigshospitalet, Denmark